ATS
ABVX

Ashton Thomas Securities’s Abivax ABVX Stock Holding History

Ashton Thomas Securities’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,500
Closed -$278K – 379
2026
Q1 		$278K Buy
+2,500
New +$296K 0.03% 306
2025
Q4 		– Sell
-2,500
Closed -$212K – 298
2025
Q3 		$212K Buy
+2,500
New +$153K 0.03% 307

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ashton Thomas Securities's ABVX Position: Q2 2026 in Review

Ashton Thomas Securities sold out of Abivax (ABVX) in Q2 2026, closing a stake of 2,500 shares — an estimated $278K sold.

Ashton Thomas Securities first reported a position in ABVX in Q3 2025 and held it in 2 quarters. The position peaked at $278K in Q1 2026. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Ashton Thomas Securities reported no remaining Abivax position as of Q2 2026 after selling out during the quarter.
  • Ashton Thomas Securities sold 2,500 Abivax shares in Q2 2026, an estimated $278K.
  • Ashton Thomas Securities first reported a position in Abivax in Q3 2025 and held it in 2 quarters.
  • Ashton Thomas Securities's Abivax position peaked at $278K in Q1 2026.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Ashton Thomas Securities's 13F filing for Q2 2026, filed 27 Jul 2026.